ANTH Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Anthera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 100.00% |
| 3 Month Change | n/a |
| 1 Year Change | 19,900.00% |
| 33 Year Change | 100.00% |
| 5 Year Change | -99.52% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ANTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19,900.0% | 2.4% | 0.5% |
| 1Y | 19,900.0% | 15.6% | 30.7% |
Return vs Industry: ANTH exceeded the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: ANTH exceeded the US Market which returned 30.7% over the past year.
Price Volatility
| ANTH volatility | |
|---|---|
| ANTH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ANTH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | John Thompson | www.anthera.com |
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company.
Anthera Pharmaceuticals, Inc. Fundamentals Summary
| ANTH fundamental statistics | |
|---|---|
| Market cap | US$5.24k |
| Earnings (TTM) | -US$24.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ANTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$28.26m |
| Gross Profit | -US$28.26m |
| Other Expenses | -US$3.33m |
| Earnings | -US$24.93m |
Last Reported Earnings
Mar 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ANTH perform over the long term?
See historical performance and comparison